SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (14144)11/16/2004 7:44:42 PM
From: Archie Meeties  Read Replies (1) of 52153
 
Angiography may be the standard, but to get at what an e2f inhibitor should do, you would either have to get the histology (most IRB's would protest) or use intravascular ultrasound. Part of the problem with angiography is that you're getting lumen size only, and not data about the changes happening in the vein. IVUS can get you both. For example, there may be massive sm hyperplasia, but lumen may remain the same because there is nothing initially restricting the growth in the diameter of the vein.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News